Department of Surgery, Fundación Santa Fé de Bogotá, 110111, Bogotá, DC, Colombia.
School of Medicine, Universidad del Rosario, Carrera 7 # 117-15, 111711, Bogotá, DC, Colombia.
BMC Surg. 2022 Jul 19;22(1):280. doi: 10.1186/s12893-022-01725-6.
Since Gagner performed the first laparoscopic adrenalectomy in 1992, laparoscopy has become the gold-standard procedure in the treatment of adrenal surgical diseases. A review of the literature indicates that the rate of intra- and postoperative complications are not negligible. This study aims to describe the single-center experience of adrenalectomies; and explore the associations between body mass index (BMI) and tumor volume in main postoperative outcomes.
Retrospective observational study with a prospective database in which we described patients who underwent adrenalectomy between January 2015 and December 2020. Operative time, intraoperative blood loss, conversion rate, complications, length of hospital stay, and comparison of the number of antihypertensive drugs used before and after surgery were analyzed. Analysis of BMI and tumor volume with postoperative outcomes such as anti-hypertensive change (AHC) in drug usage and pre-operative conditions were performed.
Forty-five adrenalectomies were performed, and all of them were carried out laparoscopically. Four were performed as a robot-assisted laparoscopy approach. Nineteen were women and 26 were men. Mean age was 54.9 ± 13.8 years. Mean tumor volume was 95.698 mm (3.75-1010.87). Mean operative time was shorter in right tumors (2.64 ± 0.75 h) than in left tumors (3.33 ± 2.73 h). Pearson correlation was performed to assess the relationship between BMI and AHC showing a direct relationship between increased BMI and higher change in anti-hypertensive drug usage at postoperative period r(45) = 0.92, p > 0.05 CI 95%. Higher tumor volume showed a longer operative time, r(45) = 0.6 (p = 0.000 CI 95%).
Obese patients could have an increased impact with surgery with an increased change in postoperative anti-hypertensive management. Tumor volume is associated with increased operative time and blood loss, our data suggest that it could be associated with increased rates of morbidity. However, further prospective studies with larger sample sizes are needed to validate our results.
自 1992 年 Gagner 进行首例腹腔镜肾上腺切除术以来,腹腔镜已成为治疗肾上腺外科疾病的金标准。文献回顾表明,术中及术后并发症的发生率不容忽视。本研究旨在描述单中心的肾上腺切除术经验;并探讨体重指数(BMI)与主要术后结果中肿瘤体积之间的关系。
这是一项回顾性观察性研究,同时建立了前瞻性数据库,我们对 2015 年 1 月至 2020 年 12 月期间接受肾上腺切除术的患者进行了描述。分析了手术时间、术中出血量、转化率、并发症、住院时间,以及手术前后使用的降压药数量的比较。分析了 BMI 和肿瘤体积与术后结果的关系,如降压药物使用的抗高血压变化(AHC)和术前情况。
共进行了 45 例肾上腺切除术,均采用腹腔镜完成。其中 4 例采用机器人辅助腹腔镜技术。19 例为女性,26 例为男性。平均年龄为 54.9±13.8 岁。平均肿瘤体积为 95.698mm(3.75-1010.87)。右肿瘤的平均手术时间较短(2.64±0.75 小时),左肿瘤的平均手术时间较长(3.33±2.73 小时)。进行了 Pearson 相关性分析,以评估 BMI 和 AHC 之间的关系,结果显示 BMI 与术后降压药物使用变化呈直接关系 r(45)=0.92,p>0.05(95%CI)。肿瘤体积越大,手术时间越长,r(45)=0.6(p=0.000,95%CI)。
肥胖患者的手术影响可能更大,术后降压治疗的变化也更大。肿瘤体积与手术时间和出血量增加有关,我们的数据表明,它可能与发病率增加有关。然而,需要进一步进行更大样本量的前瞻性研究来验证我们的结果。